Copyright
©The Author(s) 2021.
World J Clin Cases. Oct 16, 2021; 9(29): 8763-8772
Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8763
Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8763
Non-recurrent group (n = 250), n (%) | Recurrent group (n = 111), n (%) | P value | |
Age (mean ± SD) | 49.57 ± 9.22 | 51.15 ± 9.67 | 0.1395 |
Sex, male | 165 (66) | 67 (60.36) | 0.3022 |
BMI (kg/m2) (mean ± SD) | 23.74 ± 3.3 | 24.3 ± 3.69 | 0.1552 |
Smoking | 0.8010 | ||
Never | 82 (40.39) | 33 (37.93) | |
Ex-smoker | 68 (33.5) | 28 (32.18) | |
Current smoker | 53 (26.11) | 26 (29.89) | |
Alcohol consumption | 0.9465 | ||
None to minimal (< 70 g/wk) | 120 (51.28) | 51 (52.58) | |
Moderate (70-279 g/wk) | 82 (35.04) | 34 (35.05) | |
Heavy (> 280 g/wk) | 32 (13.68) | 12 (12.37) | |
Medication1 | 8 (3.4) | 3 (3.09) | 1.000 |
HTN (Yes) | 54 (21.6) | 30 (27.03) | 0.2601 |
DM (Yes) | 19 (7.6) | 6 (5.41) | 0.4485 |
Hyperlipidemia | 56 (22.4) | 29 (26.13) | 0.4413 |
Non-recurrent group (n = 250) | Recurrent group (n = 111) | P value | |
Endoscope type, n (%) | 0.0765 | ||
H260 | 157 (62.8) | 59 (53.64) | |
H290 | 90 (36) | 51 (46.36) | |
Endoscopist experience, n (%) | 0.4251 | ||
Less experienced | 75 (30) | 41 (36.94) | |
Expert | 106 (42.4) | 43 (38.74) | |
Highly expert | 69 (27.6) | 27 (24.32) | |
Midazolam dose (mean ± SD) | |||
Initial (mg) | 3.98 ± 1 | 4.19 ± 1.16 | 0.1804 |
Initial (mg/kg) | 0.06 ± 0.02 | 0.06 ± 0.02 | 0.4070 |
Total (mg) | 5.49 ± 2.04 | 6.74 ± 2.58 | < 0.0001 |
Total (mg/kg) | 0.08 ± 0.04 | 0.1 ± 0.04 | < 0.0001 |
Midazolam dose administered in previous endoscopy1 (mean ± SD) | |||
Initial (mg) | 3.78 ± 0.95 | 3.84 ± 1.04 | 0.7277 |
Initial (mg/kg) | 0.06 ± 0.02 | 0.06 ± 0.02 | 0.8448 |
Total (mg) | 7.43 ± 2.79 | 7.4 ± 2.37 | 0.6087 |
Total (mg/kg) | 0.11 ± 0.05 | 0.11 ± 0.04 | 0.4360 |
Δ Midazolam dose difference (total) (mg) | |||
Median value (quartile 25%, 75%) | -2 (-3, 0) | -1 (-2, 1) | < 0.0001 |
OR | 95%CI | P value1 | ||
Age | 1.005 | 0.978 | 1.034 | 0.7025 |
Female gender (vs male) | 1.521 | 0.731 | 3.164 | 0.262 |
BMI | 1.072 | 0.992 | 1.158 | 0.0797 |
Smoking | ||||
Ex-smoker (vs never smoker) | 1.07 | 0.484 | 2.366 | 0.8673 |
Current smoker (vs never smoker) | 1.311 | 0.572 | 3.007 | 0.522 |
Alcohol | ||||
Moderate (vs none to minimal) | 1.283 | 0.683 | 2.409 | 0.438 |
Heavy (vs none to minimal) | 0.925 | 0.413 | 2.075 | 0.8504 |
Medication2: Yes (vs no) | 1.055 | 0.242 | 4.598 | 0.9436 |
Endoscope type: H260 (vs H290) | 1.405 | 0.854 | 2.312 | 0.1808 |
Endoscopist experience | ||||
Expert (vs less experienced) | 0.712 | 0.403 | 1.256 | 0.2407 |
Highly expert (vs less experienced) | 0.822 | 0.434 | 1.557 | 0.5477 |
Δ Midazolam dose difference (total) (mg) | 1.213 | 1.099 | 1.338 | 0.0001 |
- Citation: Jin EH, Song JH, Lee J, Bae JH, Chung SJ. Midazolam dose is associated with recurrence of paradoxical reactions during endoscopy. World J Clin Cases 2021; 9(29): 8763-8772
- URL: https://www.wjgnet.com/2307-8960/full/v9/i29/8763.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i29.8763